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Abstract
Background: Schizophrenia is a complex, polygenic disorder for which over 100 genetic variants have been
identified that correlate with diagnosis. However, the biological mechanisms underpinning the different symptom
clusters remain undefined. The rs1344706 single nucleotide polymorphism within ZNF804A was among the first
genetic variants found to be associated with schizophrenia. Previously, neuroimaging and cognitive studies have
revealed several associations between rs1344706 and brain structure and function. The aim of this study is to use a
recall-by-genotype (RBG) design to investigate the biological basis for the association of ZNF804A variants with
schizophrenia. A RBG study, implemented in a population cohort, will be used to evaluate the impact of genetic
variation at rs1344706 on sleep neurophysiology and procedural memory consolidation in healthy participants.
Methods/Design: Participants will be recruited from the Avon Longitudinal Study of Parents and Children
(ALSPAC) on the basis of genotype at rs1344706 (n = 24). Each participant will be asked to take part in two
nights of in-depth sleep monitoring (polysomnography) allowing collection of neurophysiological sleep data
in a manner not amenable to large-scale study. Sleep questionnaires will be used to assess general sleep
quality and subjective sleep experience after each in-house recording. A motor sequencing task (MST) will be
performed before and after the second night of polysomnography. In order to gather additional data about
habitual sleep behaviour participants will be asked to wear a wrist worn activity monitor (actiwatch) and
complete a sleep diary for two weeks.
Discussion: This study will explore the biological function of ZNF804A genotype (rs1344706) in healthy
volunteers by examining detailed features of sleep architecture and physiology in relation to motor learning.
Using a RBG approach will enable us to collect precise and detailed phenotypic data whilst achieving an
informative biological gradient. It would not be feasible to collect such data in the large sample sizes that
would be required under a random sampling scheme. By dissecting the role of individual variants associated
with schizophrenia in this way, we can begin to unravel the complex genetic mechanisms of psychiatric
disorders and pave the way for future development of novel therapeutic approaches.
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Background
Genome wide association studies (GWAS) and subse-
quent large-scale meta-analyses have been extremely
successful in identifying large numbers of associations
(>100) between common genetic variants and schizo-
phrenia [1]. However, one limitation of this approach is
that phenotypic precision is often sacrificed in favour of
the larger sample sizes needed to override the power
constraints that come from both the limitations to meas-
urement and small genetic effects associated with com-
mon genetic variation. The reduction of complex traits
such as schizophrenia to the binary classification of
case/control in GWAS leaves much uncertainty around
the exact role of many of the associated variants in the
aetiology of disease.
In a GWAS of 479 patients with schizophrenia and
2937 controls (with replication of associated variants in
a further 16,726 subjects) the strongest evidence for
association was shown for rs1344706 (odds ratio [OR]
1.12, p = 1.95 × 10−7), a single nucleotide polymorph-
ism (SNP) within the ZNF804A gene [2]. This finding
has since been replicated in a number of other
GWAS [1, 3–5] including a fine-mapping study that failed
to detect any genetic variants within the ZNF804A locus
that were more strongly associated with schizophrenia
than rs1344706, which in this analysis had an OR for
schizophrenia of 1.10 [1.07 – 1.14] [6].
Since its discovery, rs1344706 has been linked to a
number of biological phenotypes [7]. The variant has
been shown to correlate with altered neuroanatomy
[8–11], abnormal neurophysiology [12, 13] and in par-
ticular changes in neurocognitive phenotypes [11, 14].
For example, researchers using functional magnetic
imaging (fMRI) found evidence that healthy subjects
carrying the rs1344706 risk variant showed changes in
functional connectivity of the right dorsolateral pre-
frontal cortex during a working memory task [15, 16].
Whilst cognitive defects are an established and well-
studied feature of schizophrenia [17, 18], more recently,
links have been made between the cognitive symptom di-
mension and another feature of the condition - abnormal
sleep patterns. Sleep disturbances have long been de-
scribed in schizophrenia [19, 20] with studies consistently
reporting altered sleep architecture where patients show
increased sleep latency (time taken to fall asleep), de-
creased total sleep time and other altered sleep variables -
both on neuroleptic treatment and in the absence of
medication [21, 22].
Sleep itself is a highly complex process that is tightly
controlled by circadian rhythms and homeostatic mech-
anisms [23]. Sleep is known to be important for memory
consolidation in both animals and humans [24, 25]
with studies having shown improvements in both pro-
cedural and declarative memory consolidation following
sleep [26]. Whilst even short naps lasting minutes to
hours can result in better task performance compared to
performance after an equally long period of wake time,
longer periods of sleep lead to continued memory consoli-
dation [27–29]. Moreover, sleep deprivation can severely
impair memory consolidation [30]. The importance of
sleep for memory consolidation in healthy participants is
corroborated by impaired sleep-dependent memory con-
solidation in schizophrenia patients [31].
Human sleep can be classified into stages based on
key features observed when monitoring brain activity
(Electroencephalography; EEG), eye movement
(Electrooculography; EOG) and muscle tone (Electro-
myography; EMG). The two main sleep stages are
rapid eye movement (REM) sleep and non-rapid eye
movement (NREM) sleep (further divided into stages
1–3) [32, 33]. In particular NREM sleep has been
linked to memory consolidation in healthy volunteers
[30]. More specifically, memory consolidation has
been shown to correlate with spindle activity [34–36].
Spindle oscillations (a train of distinctive waves; 11–
16 Hz, ≥0.5 s) are a feature found in the EEG during
lighter NREM (stage 2) and arise from neuronal net-
work oscillations spanning the cortex and thalamus.
Spindle activity has also been shown to be reduced in
patients with schizophrenia [37], and reduced spindle
number and density correlated with impaired overnight
improvement in a motor sequence task (MST) [38] (also
in patients). Overall there is growing evidence that circuit
abnormalities in schizophrenia link to changes in sleep
physiology which in turn may contribute to the cognitive
symptoms of schizophrenia [39, 40].
To the best of our knowledge the potential impact of
variation in ZNF804A on sleep neurophysiology in pa-
tients with schizophrenia has not been characterised.
The study of sleep phenotypes in patients with schizo-
phrenia can be challenging, both in terms of recruitment
of participants and study implementation. In many in-
stances, issues around ethics, safety, and illness limit re-
cruitment and bias samples to those with relatively mild
disease severity. Further, results may be confounded by
factors that are difficult to control, for example, medica-
tion. Where associations are observed, there are also
issues around establishing the direction of causality. So
far, efforts have been made to minimise limitations by
recruiting medication-naïve participants [22] and by
studying phenotypes in the first degree relatives of pa-
tients with schizophrenia [41]. We consider the value of
an approach whereby the genetic control of phenotypes
relevant to disease is investigated in healthy people,
avoiding the aforementioned difficulties of working with
patient groups.
Here we present a protocol designed to evaluate the
efficacy of a recall-by-genotype (RBG) study design in
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investigating the impact of ZNF804A genotype
(rs1344706) on sleep neurophysiology and memory
consolidation in healthy subjects. In RBG studies, a
sub-set of participants from an existing study are re-
cruited on the basis of measured genotypic variation;
existing biosamples can then be analysed or new data
collected. This study has the potential to improve our
understanding of both the genetic and neurophysio-
logical basis of sleep and the biological basis for the
association of ZNF804A variants with schizophrenia.
In the longer term, linking sleep disturbances to cog-
nitive deficits in psychiatric disorders could open up
new avenues for the treatment of cognitive symptoms.
Restoring normal sleep patterns in patients with psy-
chiatric disorders may improve cognition, well-being
and overall patient outcome [21].
Methods/Design
Study design
A RBG design will be implemented in a population-
based cohort. Participants will be recruited based on
their genotype at rs1344706 and extended sleep-wake
and cognitive testing datasets will be collected to allow
detailed characterization of phenotypes.
Ethical considerations and informed consent
Ethical approval for the study has been obtained from
the ALSPAC Ethics and Law Committee (ref. 9224). The
data collection protocol has also previously been ap-
proved by The University of Bristol Faculty of Science
Human Research Ethics Committee as part of a pilot
study led by MWJ (ref. 8089). All participants will re-
ceive a participant information sheet prior to being
recruited to the study and will be given the opportunity
to ask questions both at the telephone screening and
during the study nights. All participants will be asked to
complete a written consent form on their first visit and
they will be asked for continued consent verbally on
their second visit. Participants will be free to withdraw
from the study at any time. Participants will be appropri-
ately reimbursed for their time and effort (as judged
against other contemporary study initiatives) and all
travel expenses will be reimbursed.
Participant recruitment
Male participants of European ancestry aged 21–23
years will be recruited from the Avon Longitudinal Study
of Parents and Children (ALSPAC) on the basis of
homozygous status at rs1344706. Homozygotes will be
identified using existing genome-wide data, as imputed
to the 1000 genomes reference panel (Phase 1, Version 3)
(for more details on the genotyping and imputation of the
cohort, see Additional file 1). ALSPAC is a trans-
generational prospective birth cohort that began with the
recruitment of 14,541 pregnant women resident in Avon,
UK with expected dates of delivery 1st April 1991 to
31st December 1992. Since then, the health and de-
velopment of mothers and their children has been
followed across the life-course [42] (for more details
about the cohort, see Additional file 1). The target
sample size for this study will be 24, made up of 12
minor (CC) and 12 major (AA) homozygotes at
rs1344706; in the event that the genotype groups are
not equal, recruitment will continue until there is a
minimum of 12 participants in each. Researchers will
remain blind to participant genotype throughout the
recruitment and data collection phases of the study.
Invitations will be sent to selected ALSPAC partici-
pants, together with a participant information sheet
and reply slip, in batches of 100, with an even split
between the two genotype groups until the target
sample size is reached. Invitations will be sent prefer-
entially to ALSPAC participants for whom other rele-
vant phenotypic data is already available; these include
WISC (Wechsler Intelligence Scale for Children) re-
sults, n-back task data and PLIKS (Psychosis-like
symptoms) questionnaire data. An overview of the
participant recruitment process is shown in Fig. 1. All
participants who volunteer to take part will undergo a
telephone screening to check eligibility against the
following criteria:
Inclusion criteria
 In good physical or mental health;
 Non-smoker;
 Able to give informed consent as judged by the
investigator;
 Available to attend two overnight clinic visits.
Exclusion criteria
 Previously diagnosed with a sleep disorder;
 Substantive current or past medical history;
 Taking medications that may affect or induce sleep;
 Working a regular night shift (or has done within
the last six months);
 Current substance abuse, including alcohol excess
(more than 24 units a week).
Participants will be asked to refrain from drinking
alcohol in the 24 h prior to attending the clinic. They
will also be advised not to consume any caffeine-
containing drinks after 4 pm on the day of their visit to
the clinic. Participants will be asked a series of screening
questions at each visit to verify their adherence to these
instructions and to confirm their on-going eligibility for
the study.
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Data collection
The data collection phase for each participant will be
two weeks long, beginning and ending with a night
spent in the sleep suite at the clinic during which a poly-
somnography (PSG) will be performed.
Actigraphy and sleep diary
During their first visit to the clinic, the participants
will be issued with a wrist worn activity monitor
(MotionWatch 8, CamNtech, UK), which they will be
asked to wear for the two weeks between overnight
sleep monitoring nights. The MotionWatch contains a
miniature accelerometer to allow measurement and
recording of physical movement of the wrist, which pro-
vides a close correlation to whole body movement [43].
These data are stored into an internal memory and then
downloaded for analysis at the end of the study period
and analysed using MotionWare software [43]. Partici-
pants will also be asked to record information about their
bedtime, wake/rise times, naps, daytime activities and caf-
feine and alcohol intake in a standardised diary for the
duration of actigraphic monitoring. This will provide
detailed information about the participant’s habitual sleep
behaviour with the diary information aiding interpretation
of the actigraphy data. Both the MotionWatch and diary
will be returned by the participant when they attend the
clinic for the second time.
Questionnaires
Further behavioural data will be collected from each par-
ticipant using a series of questionnaires. The Pittsburgh
Sleep Quality Index (PSQI) [44] and Bristol Sleep Profile
(BSP) [45] will be used at the first visit to assess the self-
rated sleep quality and to indicate any specific sleep dis-
turbance, respectively. Each participant will also be
asked to complete the Edinburgh Handedness Inventory
[46] which will be used to ascertain participant handed-
ness ahead of the MST (see below). After each PSG re-
cording, participants will be asked to complete the St
Mary’s Hospital Sleep Questionnaire (SMH) [47] and the
Leeds Sleep Evaluation Questionnaire (LSEQ) [48]; to
collect information about subjective experience of their
night in the sleep laboratory, as compared to a normal
night.
Fig. 1 Study Workflow. Tasks in red were carried out by ALSPAC staff (not researchers) in order that researchers remained blind to participant
genotype (ALSPAC – Avon Longitudinal Study of Parents and Children; BSP – Bristol Sleep Profile; LSEQ - Leeds Sleep evaluation Questionnaire;
PSG – polysomnography; PSQI –Pittsburgh Sleep Quality Index; SMH - St Mary’s Hospital Sleep Questionnaire)
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Polysomnography
Each participant will stay in the sleep suite for two nights,
one habituation night and one test night. A standard in-
laboratory, overnight polysomnography (PSG), including
video and audio recording, will be performed using
Embla® sleep diagnostics equipment and RemLogic™ soft-
ware (Natus Medical Inc., California). Electrodes will be
placed according to the internationally standardised 10–
20 system and data acquired using a standard PSG record-
ing montage. Additional electrodes will be placed to
monitor eye movements, submental muscle activity and
heart rate throughout the recording. Following electrode
placement and bio-calibration, the participant will be able
to follow their usual evening routine and will be encour-
aged to go to bed at their usual bedtime. The participant
will be woken as close as possible to their usual wake time
and the sensors removed. Following the completion of the
data collection phase of the study, PSG data will be manu-
ally scored by an experienced expert, blinded to partici-
pant genotype, based on standardised criteria [32, 33]. A
range of sleep variables will then be derived from the an-
notated PSG recordings (see Table 1).
Motor sequence task
On their second visit participants will perform a MST
[38] approximately two hours before they go to bed and
again the following morning. Prior to completing the
MST the participant will be asked to complete the
Stanford Sleepiness Scale [49]. During the task partici-
pants will be shown a sequence of numbers consisting of
5 elements (4-1-2-3-4) on a computer. They will be
asked to type out this sequence with their non-dominant
hand as fast and as accurately as possible for 30 s. Fol-
lowing this they will be given a 30 s break. This will be
repeated 12 times.
Data analysis
A range of primary and secondary outcome measures
will be derived from the raw data, as outlined in Table 1.
We plan to examine the difference in primary outcome
measures across the recall strata, including a range of
sleep variables and performance in the MST task.
Discussion
Here we describe a study to investigate the impact of se-
quence variation in ZNF804A on sleep neurophysiology
and memory consolidation in healthy subjects. Existing
research shows that the rs1344706 variant in ZNF804A
is associated with schizophrenia and a range of neuro-
anatomical and neurocognitive phenotypes. It is also
known that in patients with schizophrenia, abnormal
sleep phenotypes are associated with poorer memory
Table 1 A summary of data collected and corresponding outcome measures
Data source Outcome measures
Primary outcome measures Polysomnography Sleep variables derived from scored recordings, e.g. total sleep
time (TST), sleep onset latency (SOL), sleep efficiency (SE),
wake after sleep onset (WASO)
Time spent in each sleep stage; S1, S2, Slow wave sleep (SWS)
and rapid eye movement sleep (REM)
Spectral composition of EEG data (delta, theta, alpha, sigma and
beta frequency bands)
Motor sequence task Number of correct sequences pre- and post-sleep
Percentage improvement
Reaction time pre- and post-sleep
Secondary outcome measures Actigraphy Sleep/Wake estimates e.g. sleep period, sleep efficiency,
total sleep time.
Non-parametric circadian rhythm analysis (NPCA) e.g. 10 most
active hours (M10), 5 least active hours (L5)
Daily activity levels
Sleep diary Detailed information about rest/activity routine (to aid interpretation
of actigraphy)
Pittsburgh Sleep Quality Index Sleep quality (over previous month)
Bristol Sleep Profile Assessment for sleep disorders (eligibility)
St Mary’s Hospital Sleep Questionnaire Sleep quality, latency, continuity, satisfaction etc. (study nights)
Leeds Sleep Evaluation Questionnaire Total Score and individual components; Getting to sleep, quality
of sleep, awake following sleep, behaviours following awakening
(study nights)
Stanford Sleepiness Scale Assessment of alertness prior to MST
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consolidation during sleep. Building on this knowledge,
this study aims to elucidate the aetiology of the associ-
ation of rs1344706 with schizophrenia, in particular,
whether the variant influences sleep neurophysiology and
has a corresponding effect on memory consolidation.
The use of a RBG study design provides important ad-
vantages for this type of research question. It allows for
more targeted selection of participants and as a result
increases the efficiency of research and focuses the dis-
tribution of resources [50]. Participants, whose genotype
has previously been determined, can be selected on the
basis of having a certain genetic variant that is thought
to contribute to a specific functional change. As a result
fewer participants need to be recruited to achieve
equivalent power to a similar population based study. In
this study we will aim to recruit 24 participants, 12 in
each homozygote genotype group. In comparison, based
on a minor homozygote (CC) frequency for rs1344706
of 17 % in the ALSPAC cohort, approximately 70 indi-
viduals would need to be recruited and genotyped to en-
sure a similar number of participants in the minor
homozygote group. This amounts to an approximate
tripling of the study time required under the RBG model
if a random sampling approach was used (from ~480 h
to ~1400 h).
This property of RBG is particularly important when
the data collection procedure is particularly labour
and/or time intensive as in this study. In this sense, a
RBG design represents the antithesis of GWAS with
sample size able to be sacrificed in favour of pheno-
typic precision, with the guaranteed biological gradi-
ent providing optimal statistical power. We also
expect rs1344706 to show larger effects as a result of
using indices of neurophysiological function rather
than exclusively cognitive measures [14]. Furthermore,
the RBG approach builds on the theoretical develop-
ments around causal inference derived from Mendelian
randomization and as such avoids the issues of confound-
ing and reverse causality that commonly effect traditional
observational studies [51].
Whilst the use of a RBG study design provides a new
and powerful approach to research into the effects of
genetic variation on phenotypes, it also creates new eth-
ical challenges that should be considered [52]. It is im-
portant to provide information to participants about
why they have been invited to the study but at the same
time not to disclose genetic information, especially when
the clinical consequences of this information are unclear
or unknown. When this study was conceived careful
consideration was given to its ethical implications. Both
the ALSPAC Ethics and Law Committee and the
ALSPAC Original Cohort Advisory Panel (OCAP) were
consulted on decisions regarding recruitment and the
disclosure of information to participants. In addition
impartial information will be collected on the ethical is-
sues surrounding the study. Whilst no individual genetic
information will be disclosed, participants will be in-
formed that they were recruited on the basis of their
genotype and they will be given opportunities to ask
questions about the study and RBG recruitment method.
Researchers will remain blind to participant genotype
throughout the data collection phase of the study, with
genotype information only being released following the
anonymization of the study data.
In summary, a RBG study is described that will con-
tribute to our understanding of the aetiology of variation
in sleep neurophysiology and the impact of genetic vari-
ants on this. By exploiting the analytical gains afforded
through extremely precise phenotyping over informative
genetic strata, this approach can simultaneously be fi-
nancially viable (due to relatively small sample sizes) and
analytically efficient. This study will help to further un-
derstanding of the neurophysiology of sleep and sleep
disturbances. Whilst the sleep phenotypes studied may
not necessarily be linked directly to disease, they could
nevertheless provide information on pre-morbid pheno-
types and improve understanding of disease pathophysi-
ology. Following the completion of this pilot study, the
results will be used to inform the planning of further
larger studies, which may also look at other genetic vari-
ants associated with schizophrenia.
Additional file
Additional file 1: The Avon Longitudinal Study of Parents and
Children. This file contains a description of the cohort used for the
study, including details of participant recruitment and genotyping and
imputation procedures. (PDF 72 kb)
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